Elsevier regrets faux journals

Elsevier came under fire for a series of deceptive publications published in Australia between 2000 and 2005. The six journals in question, published by Elsevier's Excerpta Medica, resembled legitimate journals, but were in fact sponsored compilations created “on behalf of pharmaceutical clients…and lack[ing] the proper disclosures,” said Michael Hanson, CEO of Elsevier's health sciences division, in a statement. “This was an unacceptable practice, and we regret that it took place.”

One of the journals, Australasian Journal of Bone and Joint Medicine, was allegedly produced entirely by Merck to promote Vioxx, according to a report in The Australian.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.